Tradestie Institutional Equity Comparison Engine

MRNA vs VOR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

VOR Overall Edge

VOR Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Vor Biopharma Inc. Common Stock (VOR) driven by superior Growth & Margin, Options & Structure while MRNA counters with relative strength in Valuation, Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus VOR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against VOR sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
MRNA 23.0x vs VOR N/M Fwd P/E
Growth & Margin Winner VOR
Op Margin -80.8% vs 0.0% ยท YoY +29.2% vs +0.0%
Momentum & Technical Winner MRNA
1Y +706.5% vs +145.4% ยท 52W Pos 67% vs 65%
Options & Structure Winner VOR
CONSOLIDATION (52nd %ile IV) vs CONSOLIDATION (6th %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
VOR NASDAQ
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$19.19
+3.62% 1D
Market Cap $1.1B
1M Return +1.32%
1Y Return +145.4%
Forward P/E N/M
Unified AI Score
62.7 / 100 BUY
Tech 68.0 Fund 64.0 Flow 68.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% VOR +145.4% Spread: +561.05 pp (MRNA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MRNA TTM Op. Margin: -80.8% VOR TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs VOR. Trailing 12-month operating profitability (MRNA -80.8% vs VOR 0.0%) and valuation multiples (MRNA 23.0x vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (5) vs VOR (5)
Institutional Metric MRNA VOR Criterion Row Winner
Market Capitalization Scale $80.7B $1.1B Larger Scale MRNA
Trailing P/E Ratio Valuation 23.0x 0.1x Lower Multiple VOR
Forward P/E Ratio Valuation 23.0x N/M Lower Multiple MRNA
Revenue Growth (YoY) Growth +29.2% +0.0% Higher Growth MRNA
Operating Margin (TTM) Profitability -80.8% 0.0% Higher Margin VOR
Net Profit Margin Profitability -110.5% 0.0% Higher Margin VOR
Return on Equity (ROE) Capital Efficiency -34.5% -125.4% Higher ROE MRNA
52-Week Range Position Momentum 67% ($22โ€“$281) 65% ($6โ€“$26) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 1.61ฮฒ ยท 62% Vol Lower Realized Risk VOR
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 62.7 / 100 (BUY) Higher Composite VOR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs VOR Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VOR CONSOLIDATION
56d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live VOR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor VOR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.